An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.

Trial Profile

An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Golotimod (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SciClone Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2012 Actual patient number is (12) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).
    • 07 Mar 2012 Actual end date is (1 Mar 2012) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).
    • 07 Mar 2012 Actual initiaion date is (1 Aug 2010) as reported by ClinicalTrials.gov (Extension trial; NCT01310205).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top